Literature DB >> 31414497

Quercetin administration post-weaning attenuates high-fructose, high-cholesterol diet-induced hepatic steatosis in growing, female, Sprague Dawley rat pups.

Janine Donaldson1, Mandisa Ngema1, Pilani Nkomozepi2, Kennedy Erlwanger1.   

Abstract

BACKGROUND: Fructose and cholesterol-rich diets have been implicated in the upsurge of metabolic syndrome (MetS). Phytochemicals are being explored as alternatives for the prevention and management of MetS. Thirty-six 21-day-old, female Sprague Dawley rats fed a high-fructose, high-cholesterol diet post-weaning were used to investigate the prophylactic potential of quercetin. Group 1 was given standard rat chow (SRC); Group 2: SRC and quercetin (75 mg kg-1 daily); Group 3: SRC and fenofibrate (100 mg kg-1 daily); Group 4 was given a high cholesterol diet (HCD) (2% added dietary cholesterol in SRC), 20% fructose drinking solution (FS); Group 5 was given HCD, 20% FS and quercetin (75 mg kg-1 daily); Group 6: HCD, 20% FS and fenofibrate (100 mg kg-1 daily). Rats were fed ad libitum for 8 weeks, euthanized, and blood and liver samples were collected.
RESULTS: The HCD and FS significantly increased (P < 0.05) absolute and relative liver masses and serum cholesterol. Fasting blood glucose, serum triglycerides, alanine transaminase, creatinine, and urea were not significantly different (P > 0.05) between groups. The HCD and FS significantly increased liver lipid yield compared to the SRC and rats receiving SRC with fenofibrate (P < 0.05). Quercetin or fenofibrate together with HCD and FS attenuated the diet-induced increase in liver lipids by approximately 50%, although this was not statistically significant. Liver macro- and micro-steatosis scores were significantly increased (P < 0.05) in rats receiving HCD and FS. Quercetin or fenofibrate administration together with HCD and FS significantly decreased (P < 0.05) liver macro-steatosis scores.
CONCLUSION: The prophylactic effect of quercetin on fructose and cholesterol diet-induced liver lipid accumulation may be exploited in the fight against non-alcoholic fatty liver disease (NAFLD).
© 2019 Society of Chemical Industry. © 2019 Society of Chemical Industry.

Entities:  

Keywords:  high-fructose, high-cholesterol diet; liver; metabolic health; quercetin; rat

Mesh:

Substances:

Year:  2019        PMID: 31414497     DOI: 10.1002/jsfa.9984

Source DB:  PubMed          Journal:  J Sci Food Agric        ISSN: 0022-5142            Impact factor:   3.638


  3 in total

Review 1.  Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications.

Authors:  Maria Sotiropoulou; Ioannis Katsaros; Michail Vailas; Irene Lidoriki; George V Papatheodoridis; Nikolaos G Kostomitsopoulos; Georgia Valsami; Alexandra Tsaroucha; Dimitrios Schizas
Journal:  Saudi J Gastroenterol       Date:  2021 Nov-Dec       Impact factor: 2.485

2.  Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology.

Authors:  Yingying Liu; Yingying Tan; Jiaqi Huang; Chao Wu; Xiaotian Fan; Antony Stalin; Shan Lu; Haojia Wang; Jingyuan Zhang; Fanqin Zhang; Zhishan Wu; Bing Li; Zhihong Huang; Meilin Chen; Guoliang Cheng; Yanfang Mou; Jiarui Wu
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

3.  Molecular basis of quercetin as a plausible common denominator of macrophage-cholesterol-fenofibrate dependent potential COVID-19 treatment axis.

Authors:  Anil Pawar; Amit Pal; Kalyan Goswami; Rosanna Squitti; Mauro Rongiolettie
Journal:  Results Chem       Date:  2021-06-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.